
India's #1 Dermat-Prescribed Company Targets Hair Fall
It's not an illusion – quite a few folks see more hair fall in the summer. Sweltering heat, sun rays, sweat, and pollution fuel the perfect hurricane of scalp strain. If you're already facing thinning, postpartum hair fall, or post-disease hair fall, summer aggravates the situation. (Source: Hsiang EY, Semenov YR, Aguh C, Kwatra SG. Seasonality of hair loss: a time series analysis of Google Trends data 2004-2016. Br J Dermatol 2018;178:978–9). But cheer up: a new science-backed solution, Bontress Pro+ Scalp Serum by Glenmark is getting noticed for helping with visible hair growth, with support from dermatologists and actual test results.
The Summer Hair Fall Struggle Is Real
In the summer, sweat and sebum production are higher. Paired with dust and UV damage, this can put stress on hair follicles, make roots weaker, and cause more visible shedding. Changes in diet, hydration, and stress levels also occur during the warmer months for many people – all of which can cause seasonal hair fall. (Source: Hsiang EY, Semenov YR, Aguh C, Kwatra SG. Seasonality of hair loss: a time series analysis of Google Trends data 2004-2016. Br J Dermatol 2018;178:978–9).
This is where Bontress Pro+ Scalp Serum comes in – a clinically proven solution that's been causing ripples in the trichology world for its noticeable, visible improvements in hair growth.
Clinically Proven Results That Speak for Themselves
In a recent clinical trial done on 36 healthy men and women suffering from early-stage hair fall, the outcome was nothing less than phenomenal. (Source: Based on clinical study on volunteers who used it consistently for 84 days. Data on file. Individual results may vary. Consult a dermatologist for personalized advice.)
94% of subjects experienced noticeable hair growth in as little as 28 days
68% decrease in hair loss after 12 weeks
100% of users saw new hair growth by week 12
Individual results may differ, but this marks a breakthrough for hair science – literally.
The Science Behind the Serum: Driven by 4 Advanced Peptides
What makes Bontress Pro+ unique is its powerful combination of four clinically proven peptides, each addressing a distinct cause of hair thinning:
1. Redensyl® – Stimulates stem cells of the scalp to rebuild follicles and increase new hair growth. (Source: RedensylTM. Givaudan.com. https://www.givaudan.com/fragrance-beauty/active-beauty/products/redensyl).
2. Capixyl™ – Assists in anti-inflammatory benefits and enhancing anchorage of the hair, keeping hair from falling prematurely. (Source: CapixylTM. Folligain. http://foligain.nl/media/downloads/Capixyl.pdf).
3. Anagain™ – Increases the anagen phase (growing phase) of the hair cycle so that you keep your hair for a longer duration. (Source: AnaGainTM. Mibelle Biochemistry. https://mibellebiochemistry.com/anagaintm).
4. Procapil™ – Gives hair follicles strength and limits breakage through enhanced circulation and nutrition of the scalp. (Source: ProcapilTM. FleboIn. https://flebo.in/health/procapil-overview/).
Combined, this blend of actives targets the root causes of hair loss—not only the symptoms.
Lightweight, Non-Greasy, and Summer-Ready
Unlike most tacky oils and oily serums, Bontress Pro+ contains Pro-Lipo Neo™ Technology, which enables 2.4x greater absorption into the scalp. This means it penetrates active ingredients deeper and quicker without leaving any residue (Source: Pro-Lipo™ Neo. LucasMeyer Cosmetics. https://www.hpcimedia.com/images/PDF/LMC_Brochure_Pro-Lipo.pdf).
Its liquid, quick-drying texture makes it perfect for everyday wear, particularly in warm and humid weather. You can apply it, leave it in, and go about your day without fear of buildup or weight.
Real Stories, Real Confidence Restored
For many customers, Bontress Pro+ is a hair product, but it's also a confidence builder.
Sowmya, a teacher, remembers how hair fall made her feel emotionally: 'My hair used to be down to my knees. Then stress and scalp problems made me shed in huge clumps. Nothing helped—until Bontress Pro+. Within a matter of weeks, I noticed baby hairs returning. After four months, I'm finally back to myself again.'
Priyanka, an airline career woman, had a similar experience: 'Seeing my hair fall out was devastating. I thought I was balding. But Bontress Pro+ restored my hopes. By the third month, my hair was stronger, thicker, even healthier-looking. It's transformed my attitude towards myself.'
Click here to see our journey
Why It Works Even Better in Summer
Heat and humidity may cause scalp buildup and inflammation of follicles, exacerbating hair loss. Bontress Pro+'s light texture combats seasonal aggressors, providing moisture and nutrition without getting clogged in pores.
For best results, dermatologists advise once-daily application for a minimum of 12 weeks or as recommended by their dermatologist. While individual results may vary, most users experience changes within the first month. Consistent application results in healthier, denser, more resilient hair.
So, if you're fed up with seeing your hair fall out strand by strand, particularly in the summer months, Bontress Pro+ could be the solution you've been searching for.
'This article is part of the sponsored content programme.'
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Standard
2 days ago
- Business Standard
G.C Chemie Pharmie: Four Decades of Innovation and Trust in Pharmaceuticals and Nutraceuticals
India PR Distribution Mumbai (Maharashtra) [India], June 6: G.C Chemie Pharmie Pvt. Ltd. (GCCPL), a pioneer in India's pharmaceutical, nutraceutical, functional foods, and biopharmaceutical sectors, proudly celebrates over 44 years of innovation and service excellence. Founded in 1981 by visionary entrepreneur Gautam Shah, GCCPL has evolved into a globally connected and innovation-driven enterprise known for its commitment to trust, transparency, and quality. What began as an API trading and distribution firm has transformed into a diversified pharmaceutical powerhouse. GCCPL's impressive timeline of achievements includes: - 2009/2010: Acquisition of Eagle Chemical Works, establishing its own API manufacturing capabilities - 2009: Release of its first vaccine, marking a significant milestone in biopharmaceuticals - 2010/2011: Launch of its P2P division, introducing affordable medicines to the Indian market -2018: Entry into the sports nutrition space - 2022: Creation of a preventive healthcare division with a focus on gynecology and orthopedics - 2023: Establishment of a dedicated vaccine division to expand immunization solutions Driven by a mission to lead through innovative thinking and technology adoption, GCCPL delivers tailored solutions across pharmaceutical, nutraceutical, and functional food categories. The company continues to differentiate itself through its strong regulatory acumen, cutting-edge R & D, and a global network of manufacturing and distribution partners. "At GCCPL, innovation is not a buzzword--it's the foundation of our growth strategy," said Founder and Chairman Gautam Shah. "We're proud to be one of India's few private companies to bring the pneumococcal vaccine to the domestic market, second only to Pfizer." Recent product highlights include UC-II®, a patented undenatured type II collagen supplement, and Pylopass™, a breakthrough strain-based probiotic--both showcasing GCCPL's commitment to introducing clinically backed, innovative health solutions to India. With a sterling reputation for regulatory compliance, deep market research, and financial integrity--as affirmed by CRISIL's highest rating A2+ GCCPL stands as a trusted partner for businesses and healthcare providers seeking reliable, next-generation healthcare products. About G.C Chemie Pharmie Pvt. Ltd. Founded in 1981, GCCPL is an Indian-based pharmaceutical and nutraceutical company with a global footprint. Known for its reliability, innovation, and commitment to quality, GCCPL offers customized, technology-driven healthcare solutions to meet the evolving needs of today's market. The company maintains a strong presence in vaccines, preventive care, functional foods, and advanced supplements.


United News of India
2 days ago
- United News of India
Dr Reddy's Lab partners with Alvotech to Co-Develop & commercialize Biosimilar Candidate
Hyderabad, June 5 (UNI) Alvotech , a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Hyderabad-based Dr. Reddy's Laboratories Ltd, on Thursday announced that the companies have entered into a collaboration and license agreement to co-develop, manufacture and commercialize a biosimilar candidate to Keytruda® (pembrolizumab) for global markets. Keytruda® (pembrolizumab) is indicated for the treatment of numerous cancerTypes, Hyderabad based pharma giant said in a release here. In 2024, worldwide sales of Keytruda were US$29.5 billion. The collaboration combines and Alvotech's proven capabilities in biosimilars, thereby speeding up the development process and extending the global reach for this biosimilar candidate. Under the agreement, the parties will be jointly responsible for developing and manufacturing the biosimilar candidate and sharing costs and responsibilities. Subject to certain exceptions, each party will have the right to commercialize the product globally. 'We are very pleased to enter into this collaboration for pembrolizumab with Dr. Reddy's. This agreement demonstrates Alvotech's ability to leverage its dedicated R& D and manufacturing platform for biosimilars, accelerating the expansion of our pipeline by pursuing growing global markets. It further enables us to increase the availability of cost-effective, critical biologic medications to patient's world-wide,' said Róbert Wessman, chairman and CEO of Alvotech. Dr Reddy's CEO Erez Israeli said 'We are happy to collaborate with Alvotech for the pembrolizumab biosimilar. This demonstrates our ability to develop and manufacture high quality and affordable treatment options for patients worldwide. Additionally, oncology has been a top focus therapy area for us and this collaboration will further enhance our capabilities in oncology, as pembrolizumab currently represents one of themost critical therapies in immuno-oncology.' UNI KNR BD


Business Standard
3 days ago
- Business Standard
Servier India introduces 'Ivosidenib'(Tibsovo®), in India, First-in-class Targeted Therapy in Oncology for Rare IDH1-Mutated AML and Cholangiocarcinoma
VMPL Mumbai (Maharashtra) [India], June 5: Servier India, a subsidiary of the leading French pharmaceutical Servier Group, today announced the launch of Ivosidenib (Tibsovo®), an oral targeted therapy approved in the management of cancer patients with Acute Myeloid Leukemia (AML) and Cholangiocarcinoma, with an isocitrate dehydrogenase-1 (IDH1) mutation. Servier India received the approval on 14th May 2025, from Central Drugs Standard Control Organisation (CDSCO) for the import, sale, and distribution of the medication. Acute myeloid leukemia is a challenging hematological malignancy. Studies indicate that only about 30-40% of AML patients in India receive adequate treatment1, with high mortality rates due to rapid disease progression and infections. Cholangiocarcinomas (CCA) are rare tumours originating from bile duct. Due to their asymptomatic nature they are usually diagnosed when the disease is advanced.2 The announcement marks a significant advancement in management of the mentioned rare and difficult-to-treat cancers in India, addressing a critical unmet medical need. Speaking on the occasion, Mr. Aurelien Breton, Managing Director, Servier India, said, "Our focus is to advance oncology care by bringing innovative, precision medicines to patients who need them the most. By prioritizing access and working to make treatment options affordable to patients, we are dedicated to bridging critical gaps in cancer care across the country. This launch is a significant step forward in our mission to support healthcare providers with targeted treatment options and ultimately improve survival outcomes and quality of life for patients throughout India." IDH1 mutation occurs in approximately 7-14% of AML patients in India3, making targeted mechanisms especially relevant for this subset. "This therapy represents a significant therapeutic option in the treatment of AML and Cholangiocarcinoma. For healthcare professionals, this precision therapy offers a new, effective option that can improve patient outcomes where traditional treatments have limited success. It highlights the benefits of targeted therapy and caliber of innovation in enhancing lives and advancing cancer care in India.", highlighted Dr. Pranav Sopory, Medical and Patient Affairs Director, Servier India. Speaking on the importance of treatment access, Ms. Pratima Tripathi, Commercial Director, Servier India, said: "Our foremost priority is to ensure that the therapy is accessible and affordable to patients across India. We are actively collaborating with healthcare providers, patient advocacy groups, and policymakers to remove barriers and facilitate timely access to this important therapy. Through these partnerships, we are committed to expanding treatment options and making a meaningful difference in the lives of patients." By introducing these advanced therapies, Servier India reaffirms its commitment to advancing innovative cancer treatments that improve clinical outcomes and enhance the quality of life of patients. Disclaimer: This press release is intended solely to share regulatory and medical information regarding the launch; the reference to "Tibsovo" is not intended as a promotional or public advertisement. Use of the therapy is strictly based on a doctor's prescription and clinical discretion. About Servier India Servier India has been committed for over three decades to delivering innovative pharmaceutical solutions that improve the lives of patients and their families across India. Established in 1985 as an affiliate of the leading independent French pharmaceutical Servier Group, the company focuses on therapeutic areas such as Cardiometabolism, Neuroscience, Venous Diseases, and Oncology. Servier India has a strong pan-India presence and a dedicated workforce of around 580 that strives to address critical healthcare challenges with passion and purpose. As part of Servier group operating in over 150 countries, Servier India inherits a rich legacy of scientific excellence and patient-centric innovation. Globally, Servier invests heavily in research and development, focusing on our key therapeutic areas. About Servier Servier is a global pharmaceutical group governed by a Foundation that aspires to serve its vocation with a long-term vision: being committed to therapeutic progress to serve patient needs. As a world leader in cardiometabolism and venous diseases, Servier's ambition is to become a focused and innovative player in oncology by targeting rare cancers. Headquartered in France, Servier relies on a strong geographical footprint; its medicines are available in close to 140 group achieved a revenue of EUR5.9 billion in 2024. Additional Details on Ivosidenib Internationally, Ivosidenib has already received regulatory approvals in more than 42 countries, including the USA, Europe, China, UAE, and South Korea. In the United States, the US FDA approved it in 2019 as a monotherapy and later in May 2022 as a combination treatment with Azacitidine for patients aged 75 and above, or those who cannot tolerate intensive chemotherapy. The European Medical Agency (EMA) gave its approval in May 2023 for use in patients who are not fit for standard induction chemotherapy. In India, the process moved forward in April 2025, when the Subject Expert Committee (SEC) gave a positive recommendation for Ivosidenib. Following this, the DCGI granted approval for the marketing authorization in May 2025